BlackRock’s Oncolytics Biotech ONCY Stock Holding History

BlackRock’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85K	Hold	3,000	–	–	﹤0.01%	5523
2026 Q1	$2.55K	Hold	3,000	–	–	﹤0.01%	5504
2025 Q4	$2.62K	Hold	3,000	–	–	﹤0.01%	5381
2025 Q3	$4.2K	Hold	3,000	–	–	﹤0.01%	5278
2025 Q2	$2.32K	Hold	3,000	–	–	﹤0.01%	5313
2025 Q1	$1.65K	Hold	3,000	–	–	﹤0.01%	5307
2024 Q4	$2.74K	Buy	+3,000	New	+$3.12K	﹤0.01%	5268
2020 Q3	–	Sell	-3,895	Closed	-$7K	–	5133
2020 Q2	$7K	Hold	3,895	–	–	﹤0.01%	4812
2020 Q1	$5K	Buy	+3,895	New	+$9.7K	﹤0.01%	4774

Other funds holding ONCY

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

BlackRock's ONCY Position: Q2 2026 in Review

BlackRock held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 3,000 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #5523.

BlackRock first reported a position in ONCY in Q1 2020 and has held it in 9 quarters since. The position peaked at $7K in Q2 2020. 76 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

BlackRock held 3,000 shares of Oncolytics Biotech worth $2.85K as of Q2 2026.
BlackRock left its Oncolytics Biotech share count unchanged in Q2 2026.
Oncolytics Biotech made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5523 holding.
BlackRock first reported a position in Oncolytics Biotech in Q1 2020 and has held it in 9 quarters since.
BlackRock's Oncolytics Biotech position peaked at $7K in Q2 2020.
76 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.